Інгібітор фактора міграції макрофагів при гострому інфаркті міокарда
DOI:
https://doi.org/10.30978/UTJ2018-3-4-73Ключові слова:
інгібітор фактора міграції макрофагів, гострий інфаркт міокарда, серцево-судинні захворюванняАнотація
Інгібітор фактора міграції макрофагів (МІФ) — плейотропний прозапальний цитокін, який бере участь у розвитку багатьох гострих та хронічних запальних захворювань, в тому числі серцево-судинних. Виявлено тісний зв’язок між МІФ і гострим інфарктом міокарда (ГІМ). Водночас невідомо, якою мірою ранні циркулюючі рівні МІФ корелюють з початком і ступенем інфаркту міокарда. В огляді представлено аналіз даних останніх клінічних та експериментальних досліджень щодо ролі МІФ у патогенетичних механізмах ГІМ.Посилання
Cheuk-Man Yu, Kevin Wing-Hon Lai, Yong-Xiong Chen. Expression of Macrophage Migration Inhibitory Factor in Acute Ischemic Myocardial Injury. The Journal of Histochemistry & Cytochemistry. 2003;51(5):625-631. doi:10.1177/ 002215540305100508.
Cui J, Zhang F, Wang Y, et al. Macrophage migration inhibitory factor promotes cardiac stem cell proliferation and endothelial differentiation through the activation of the PI3K / Akt / mTOR and AMPK pathways. Int J Molecular Med. 2016;37(5):1299-1309. doi:10.3892/ijmm.2016.2542.
David A. White, Fang L, Chan W, et al. Pro-Inflammatory Action of MIF in Acute Myocardial Infarction via Activation of Peripheral Blood Mononuclear Cells. PLoS ONE. 2013;8(10). doi:10.1371/journal.pone.0076206.
David A White, Yidan Sum, Peter Kanellakis, et al. Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. J Mol Cell Cardiol. 2014;69:32-42. doi:10.1016/j.yjmcc.2014.01.015.
David JR. Delayed hypersensitivity in vitro: its mediation by cellfree substances formed by lymphoid cellantigen interaction. Proc Natl Acad Sci USA. 1966;56(1):72-77.
Di Serafino L, Bartunek J, Heyndrickx G, et al. Macrophage migration inhibitory factor(MIF) is associated with degree of collateralization in patients with totally occluded coronary arteries. Int J Cardiol. 2018;262:14-19. doi:10.1016/j.ijcard.2018.03.094.
Elisabeth Karsten, Cameron J Hill, Benjamin R Herbert. Red blood cells: The primary reservoir of macrophage migration inhibitory factor in whole blood. Cytokine. 2018;102:34-40. doi:10.1016/j.cyto.2017.12.005.
Fenling Fan, Anthony Michael Dart. GW26e1326 Exercise induced myocardial but not peripheral muscle ischemia is associated with rise in plasma macrophage migration inhibitory factor(MIF). J Am Coll Cardiol. 2015;66(16):131-132. doi:https://doi.org/10.1016/j.jacc.2015.06.507.
Fenling Fan, Lu Fang, Xiao-Lei Moore, et al. Plasma macrophage migration inhibitor factor is elevated in response to myocardial ischemia. J Am Heart Association. 2016;5(7). doi:10.1161/JAHA.115.003128.
Georgios Pantouris, Junming Ho, Dilip Shah, et al. Nanosecond Dynamics Regulate the MIF Induced Activity of CD74. Angewandte Chemie. 2018;57(24):7116-7119. doi:10.1002/anie.201803191.
Gong Z, Xing S, Zheng F, Xing Q. Increased expression of macrophage migration inhibitory factor in aorta of patients with coronary atherosclerosis. J Cardiovasc Surg. 2015;56(4):631-637.
Gregory A Roth, Catherine Johnson, Amanuel Abajobir, Foad AbdAllah. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25. doi:10.1016/j.jacc.2017.04.052.
Grieb G, Kim B.S, Simons D, Bernhagen J, Pallua N. MIF and CD74-Suitability as clinical biomarkers. Minireviews in medicinal chemistry. 2014;14(14):1125-1131. doi:10.2174/1389557515 666150203143317.
Hao Y, Yi SL, Zhong JQ. Serum macrophage migration inhibitory factor levels are associated with angiographically complex coronary lesions in patients with coronary artery disease. Genet Test Mol Biomarkers. 2015;19(10):556-560. doi:10.1089/gtmb.2015.0113.
Julia Sobierajski, Ulrike B. Hendgen-Cotta, Peter Luedike, et al. Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels. Free Radical Biology and Medicine. 2013;63:236-242. doi:10.1016/j.freeradbiomed.2013.05.018.
Kambara T, Shibata R, Ohashi K, et al. C1q/Tumor Necrosis Factor-Related Protein 9 Protects against Acute Myocardial Injury through an Adiponectin Receptor IAMPK-Dependent Mechanism. Mol Cell Biol. 2015;35(12):2173-2185. doi:10.1128/MCB.0151814.
Koga K, Kenessey A, Ojamaa K. Macrophage migration inhibitory factor antagonizes pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2013;304(2):282-293. doi:10.1152/ajpheart.00595.2012.
Liehn EA, Kanzler I, Konschalla S, et al. Compartmentalized protective and detrimental effects of endogenous macrophage migration-inhibitory factor mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion. Arterioscler Thromb Vasc Biol. 2013;33(9):2180-2186. doi:10.1161/ATVBAHA.113.301633.
Luyuan Tao, Mingyuan Huang, Saroj-Thapa, et al. Effects of macrophage migration inhibitory factor on cardiac reperfusion injury in mice with depression induced by constant-darkness. Journal of Affective Disorders. 2018;229:403-409. doi:https://doi.org/10.1016/j.jad.2017.12.039.
Meza-Romero R, Benedek G, Leng L, Bucala R, Vandenbark AA. Predicted structure of MIF/CD74 and RTL1000/CD74 complexes. Metab Brain Dis. 2016;31(2):249-255. doi:10.1007/s110110169798x.
Muller II, Muller KA, Karathanos A, et al. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin1 in patients with coronary artery disease. Atherosclerosis. 2014;237(2):426-432. doi:10.1016/j.atherosclerosis.2014.09.010.
Nalin H Dayawansa, Xiao-Ming Gao, David A White, et al. Role of MIF in myocardial ischaemia and infarction: insight from recent clinical and experimental findings. Clin Sci. 2014;127(3):149-161. doi:10.1042/CS20130828.
Pan JH, Sukhova GK, Yang JT, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2004;109(25):3149-3153. doi:10.1161/01.CIR.0000134704. 84454.D2.
Pohl J, Hendgen-Cotta UB, Rammos C, et al. Targeted intracellular accumulation of macrophage migration inhibitory factor in the reperfused heart mediates cardioprotection. Thromb Haemost. 2016;115(1):200-212. doi:10.1160/TH15050436.
Qi D, Hu X, Wu X, et al. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J Clin Invest. 2009;119(12):3807-3816. doi:10.1172/JCI39738.
Seppo Ylä-Herttuala, Jacob Fog Bentzon, Mat Daemen, Erling Falk et al. Stabilization of atherosclerotic plaques: an update. Eur Heart J. 2013;34(42):3251-3258. doi:10.1093/eurheartj/eht301.
Simons D, Grieb G, Hristov M, et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med. 2011;15(3):668-678. doi:10.1111/j.15824934. 2010.01041.x.
Stoppe C, Rex S, Goetzenich A, et al. Interaction of MIF Family Proteins in Myocardial Ischemia/Reperfusion Damage and Their Influence on Clinical Outcome of Cardiac Surgery Patients. Antioxid Redox Signal. 2015;23(11):865-879. doi:10.1089/ars.2014.6243.
Stoppe C, Werker T, Rossaint R, Dollo F, et al. What is the significance of perioperative release of macrophage migration inhibitory factor in cardiac surgery?. Antioxid Redox Signal. 2013;19(3):231-239. doi:10.1089/ars.2012.5015.
Takahashi M, Nishihira J, Katsuki T, et al. Elevation of plasma levels of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol. 2002;89(2):248-249. doi:https://doi.org/10.1016/S00029149(01)022512.
Wang J, Tong C, Yan X, et al. Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction. Circulation. 2013;128(3):225-236. doi:10.1161/CIRCULATIONAHA.112.000862.
William Chan, David A. White, et al. Macrophage Migration Inhibitory Factor for the Early Prediction of Infarct Size. J Am Heart Association. 2013;2(5). doi:10.1161/JAHA.113.000226.
WHO. The top 10 causes of death. Fact sheet. 12 January 2017. http://www.who.int/newsroom/factsheets/detail/thetop10causesofdeath.
Zhou B, Ren C, Zu L, et al. Elevated plasma migration inhibitory factor in hypertension-hyperlipidemia patients correlates with impaired endothelial function. Medicine(United States). 2016;95(43). doi:10.1097/MD.0000000000005207.